angiotensin ii, des-phe(8)- has been researched along with Impotence, Arteriogenic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costa-Fraga, FP; da Silva, D; da Silva, RF; De Sousa, FB; Fraga-Silva, RA; Mach, F; Montecucco, F; Santos, RA; Savergnini, SQ; Sinisterra, RD; Stergiopulos, N | 1 |
1 other study(ies) available for angiotensin ii, des-phe(8)- and Impotence, Arteriogenic
| Article | Year |
|---|---|
An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia.
Topics: Administration, Oral; Angiotensin I; Animals; Apolipoproteins E; Collagen; Cyclodextrins; Disease Models, Animal; Endothelium, Vascular; Fibrosis; Hypercholesterolemia; Impotence, Vasculogenic; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Oxidative Stress; Penile Erection; Penis; Peptide Fragments; Phosphoproteins; Proto-Oncogene Mas; Proto-Oncogene Proteins; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Vasodilation; Vasodilator Agents | 2013 |